Clinical Trial

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-21; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-08-07
Trial Details
NCT Number NCT07043322
Lead Sponsor Tanta University
Conditions Gynecologic Disease
Enrollment 150 participants
Start Date 2025-06-30
Primary Completion 2026-10-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-13